Emerging Options for the Prevention and Management of Clostridioides difficile Infection

Link to article at PubMed

Drugs. 2023 Feb;83(2):105-116. doi: 10.1007/s40265-022-01832-x. Epub 2023 Jan 16.


Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.

PMID:36645620 | PMC:PMC9841950 | DOI:10.1007/s40265-022-01832-x

Leave a Reply

Your email address will not be published. Required fields are marked *